Flexion Therapeutics Inc (NASDAQ:FLXN) has been assigned an average rating of “Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $99.11.
Several equities research analysts have recently commented on the stock. BidaskClub cut shares of Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 20th. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Flexion Therapeutics in a research report on Friday, November 10th. Janney Montgomery Scott raised their target price on shares of Flexion Therapeutics to $570.00 and gave the stock a “fair value” rating in a research report on Tuesday, October 10th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $37.00 target price (up from $35.00) on shares of Flexion Therapeutics in a research report on Monday, October 9th.
Shares of Flexion Therapeutics (NASDAQ FLXN) traded up $2.23 during trading on Tuesday, reaching $23.80. 1,004,566 shares of the company’s stock were exchanged, compared to its average volume of 730,231. The company has a market cap of $893.47, a price-to-earnings ratio of -6.76 and a beta of 0.91. Flexion Therapeutics has a 1-year low of $16.51 and a 1-year high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93.
Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.09). sell-side analysts expect that Flexion Therapeutics will post -3.84 earnings per share for the current year.
In other news, insider Neil Bodick acquired 2,700 shares of Flexion Therapeutics stock in a transaction on Tuesday, November 21st. The stock was acquired at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the purchase, the insider now owns 64,605 shares in the company, valued at $1,582,176.45. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael D. Clayman acquired 5,000 shares of Flexion Therapeutics stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $23.60 per share, with a total value of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares in the company, valued at approximately $835,322. The disclosure for this purchase can be found here. Company insiders own 15.98% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. increased its stake in Flexion Therapeutics by 0.6% during the 2nd quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 338 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in Flexion Therapeutics by 0.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock valued at $2,047,000 after purchasing an additional 513 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Flexion Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after purchasing an additional 811 shares in the last quarter. ProShare Advisors LLC increased its stake in Flexion Therapeutics by 5.5% during the 2nd quarter. ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company’s stock valued at $379,000 after purchasing an additional 982 shares in the last quarter. Finally, Cadence Capital Management LLC increased its stake in Flexion Therapeutics by 5.1% during the 3rd quarter. Cadence Capital Management LLC now owns 54,002 shares of the specialty pharmaceutical company’s stock valued at $1,306,000 after purchasing an additional 2,612 shares in the last quarter. Institutional investors and hedge funds own 73.21% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/06/flexion-therapeutics-inc-flxn-receives-average-rating-of-buy-from-brokerages.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.